Cargando…

Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism—A systematic review

INTRODUCTION: Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long‐term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Buch, Kristian, Gunmalm, Victoria, Andersson, Michael, Schwarz, Peter, Brøns, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346263/
https://www.ncbi.nlm.nih.gov/pubmed/30561133
http://dx.doi.org/10.1002/cam4.1911
Descripción
Sumario:INTRODUCTION: Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long‐term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechanisms remain unclear. A change in glucose and insulin metabolism is a possible consequence. METHODS: We searched PubMed on the 4th of May 2018, and found eight articles that compared measurements of glucose and insulin before and after chemotherapy and/or aromatase inhibitors in woman with BC. RESULTS: A general trend of increased glucose and insulin is seen and likely to be caused by weight gain and/or changes in body composition as a consequence of adjuvant treatment of BC. DISCUSSION: Due to methodological limitations including short follow‐up times and small sample sizes, further studies are required to better describe metabolic consequences of adjuvant chemotherapy and/or aromatase inhibitors. Future studies could help identify patients in high‐risk of developing cardiometabolic disease after BC treatment.